CD37/TSPAN26 recombinant proteins and antibodies

CD37, also known as TSPAN26, is a tetraspanin family member expressed on the surface of various immune cells, including B cells, T cells, and other immune cells. As an important immune regulatory molecule, CD37 plays various biological roles in the immune system, particularly in immune suppression and tumor immune evasion. CD37 is highly expressed in several malignancies, especially B-cell-derived tumors such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, while its expression is relatively low in normal tissues, making it a promising tumor target.

The primary function of CD37 is to regulate the activation and inhibition of immune cells through interactions with other immune regulatory molecules, helping maintain immune system balance. In the context of tumor immune evasion, CD37 may promote tumor growth and metastasis by inducing T-cell tolerance and suppressing T-cell activity. Given its high expression in B-cell tumors, CD37 has emerged as an important target in cancer immunotherapy, particularly for the treatment of B-cell-associated tumors.

Currently, ongoing drug development targeting CD37 mainly focuses on monoclonal antibody therapies. Certain CD37 monoclonal antibodies can specifically bind to and inhibit CD37, thereby modulating immune cell function and enhancing anti-tumor immune responses. For example, studies on monoclonal antibodies have shown that inhibiting CD37 can effectively increase tumor-specific immune responses and help restore the immune system’s ability to recognize and eliminate tumor cells. Additionally, some CD37-targeted antibody-drug conjugates (ADCs) are being developed to deliver cytotoxic drugs directly to tumor cells, thereby improving efficacy and reducing damage to normal tissues.

Several pharmaceutical companies have actively entered the field of CD37-targeted research and development. Global pharmaceutical giants such as AstraZeneca, Johnson & Johnson, and Sanofi have made progress in the development of CD37-targeted immunotherapies. In particular, CD37-targeted drugs hold promise for providing new treatment options for patients with B-cell tumors. These companies aim to develop more precise and effective treatment strategies through targeting the CD37 molecule, especially in cases where existing therapies have limited efficacy.

To assist in the development of CD37/TSPAN26 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD37 targets. Products include active CD37 recombinant proteins, full-length CD37 proteins, CD37 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD37 biotherapy, DIMA BIOTECH has also prepared a CD37 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD37 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.